Coseasonal Initiation of Allergen Immunotherapy: A Systematic Review

Journal of Allergy and Clinical Immunology: In Practice

Volumn 4, Issue 6, 2016, Pages 1194-1204.e4

  Creticos, Peter S ^a   Bernstein, David I ^b   Casale, Thomas B ^c   Lockey, Richard F ^c   Maloney, Jennifer ^d   Nolte, Hendrik ^d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Allergen immunotherapy; Allergic rhinoconjunctivitis; Co seasonal; In season; Initiation; Intra seasonal; Safety

Indexed keywords

ANTIHISTAMINIC AGENT; BIRCH POLLEN ANTIGEN; CORTICOSTEROID; GRASS POLLEN EXTRACT; MOUNTAIN CEDAR POLLEN ANTIGEN; PLACEBO; POLLEN ANTIGEN; TREE POLLEN ANTIGEN; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ALLERGEN IMMUNOTHERAPY; ALLERGIC REACTION; ANAPHYLAXIS; APPLICATION SITE REACTION; ARTICLE; ASTHMA; BRADYCARDIA; CLINICAL FEATURE; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL (TOPIC); COUGHING; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ECZEMA; FAINTNESS; FEVER; FLUSHING; FOREIGN BODY; HEADACHE; HUMAN; HYPOTENSION; IMMUNOTHERAPY; INJECTION SITE REACTION; INJECTION SITE SWELLING; LARYNX EDEMA; LIP DISEASE; LIP SWELLING; NASAL PRURITUS; NAUSEA; POLLEN ALLERGY; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINITIS; SEASONAL VARIATION; SIDE EFFECT; STOMACH PAIN; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; SYSTEMATIC REVIEW; TONGUE SWELLING; URTICARIA; VALIDATION PROCESS; VOICE DISORDER; VOMITING; WHEEZING; DESENSITIZATION; PROCEDURES; SEASON;

DESENSITIZATION, IMMUNOLOGIC; HUMANS; SEASONS;

EID: 84977521834     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2016.05.014     Document Type: Article

References (65)

1. 1 Wallace, D.V., Dykewicz, M.S., Bernstein, D.I., Blessing-Moore, J., Cox, L., Khan, D.A., et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol 122 (2008), S1–S84.
2. 2 Bernstein, D.I., Wanner, M., Borish, L., Liss, G.M., Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin Immunol 113 (2004), 1129–1136.
3. 3 Amin, H.S., Liss, G.M., Bernstein, D.I., Evaluation of near-fatal reactions to allergen immunotherapy injections. J Allergy Clin Immunol 117 (2006), 169–175.
4. 4 Reid, M.J., Lockey, R.F., Turkeltaub, P.C., Platts-Mills, T.A., Survey of fatalities from skin testing and immunotherapy 1985-1989. J Allergy Clin Immunol 92 (1993), 6–15.
5. 5 Epstein, T.G., Liss, G.M., Murphy-Berendts, K., Bernstein, D.I., AAAAI/ACAAI surveillance study of subcutaneous immunotherapy, years 2008-2012: an update on fatal and nonfatal systemic allergic reactions. J Allergy Clin Immunol Pract 2 (2014), 161–167.
6. 6 Tinkelman, D.G., Cole, W.Q. III, Tunno, J., Immunotherapy: a one-year prospective study to evaluate risk factors of systemic reactions. J Allergy Clin Immunol 95 (1995), 8–14.
7. 7 Calderon, M.A., Simons, F.E., Malling, H.J., Lockey, R.F., Moingeon, P., Demoly, P., Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy 67 (2012), 302–311.
8. 8 Cox, L., Nelson, H., Lockey, R., Calabria, C., Chacko, T., Finegold, I., et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 127 (2011), S1–S55.
9. 9 Zuberbier, T., Bachert, C., Bousquet, P.J., Passalacqua, G., Walter Canonica, G., Merk, H., et al. GA(2) LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma. Allergy 65 (2010), 1525–1530.
10. 10 Pfaar, O., Bachert, C., Bufe, A., Buhl, R., Ebner, C., Eng, P., et al. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases. Allergo J Int 23 (2014), 282–319.
11. 11 Alvarez-Cuesta, E., Bousquet, J., Canonica, G.W., Durham, S.R., Malling, H.J., Valovirta, E., et al. Standards for practical allergen-specific immunotherapy. Allergy 61 (2006), 1–20.
12. 12 Liberati, A., Altman, D.G., Tetzlaff, J., Mulrow, C., Gotzsche, P.C., Ioannidis, J.P., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62 (2009), e1–e34.
13. 13 Reiber, R., Wolf, H., Schnitker, J., Wustenberg, E., Intra-seasonal short-time up-dosing with SQ-standardised subcutaneous immunotherapy in patients with intermittent allergic rhinoconjunctivitis is well tolerated during routine application: a non-interventional observational study. J Allergy Ther, 4, 2013, 137.
14. 14 Stelzer, T., Bubel, P., Tree pollen allergic patients can be safely treated with cluster immunotherapy. Allergy, 68, 2013, 586.
15. 15 Werner, G., Cluster immunotherapy can be safely initiated extra and intra-seasonally for grass pollen allergic patients. Allergy, 68, 2013, 546.
16. 16 Sieber, J., Koberlein, J., Mosges, R., Sublingual immunotherapy in daily medical practice: effectiveness of different treatment schedules—IPD meta-analysis. Curr Med Res Opin 26 (2010), 925–932.
17. 17 Ariano, R., Incorvaia, C., La Grutta, S., Marcucci, F., Pajno, G., Sensi, L., et al. Safety of sublingual immunotherapy started during the pollen season. Curr Med Res Opin 25 (2009), 103–107.
18. 18 Leonardi, S., Arena, A., Bruno, M.E., Cannao, P.M., D'Anneo, R.W., Falagiani, P., et al. Olea sublingual allergoid immunotherapy administered with two different treatment regimens. Allergy Asthma Proc 31 (2010), e25–e29.
19. 19 Pajno, G.B., Caminiti, L., Crisafulli, G., Vita, D., Valenzise, M., De Luca, R., et al. Direct comparison between continuous and coseasonal regimen for sublingual immunotherapy in children with grass allergy: a randomized controlled study. Pediatr Allergy Immunol 22 (2011), 803–807.
20. 20 Schwab, J.A., Wolf, H., Schnitker, J., Wustenberg, E., Safety and tolerability of an intra-seasonal initiation of the sq-standardised grass allergy immunotherapy tablet: a non-interventional observational study investigating the feasibility during routine administration. Clin Drug Investig 33 (2013), 719–726.
21. 21 Klimek, L., Sager, A., Klein, C., Pfaar, O., INSIDE—safety and efficacy of an intraseasonal short-time subcutaneous immunotherapy with a modified depigmented birch-pollen extract. Allergy, 68, 2013, 478.
22. 22 Lee, L.K., Kniker, W.T., Campos, T., Aggressive coseasonal immunotherapy in mountain cedar pollen allergy. Arch Otolaryngol 108 (1982), 787–794.
23. 23 Pfaar, O., Wolf, H., Klimek, L., Schnitker, J., Wustenberg, E., Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial. Clin Ther 34 (2012), 2072–2081.
24. 24 Paterok, P., Co-seasonal initiation of cluster-immunotherapy with highly polymerised grass pollen extracts is a safe treatment. Allergy, 67, 2012, 234.
25. 25 Bubel, P., Safety profile and compliance of co-seasonal initiation of specific subcutaneous immunotherapy with a highly polymerised allergen extract. Allergy, 65, 2010, 581.
26. 26 D'Anneo, R.W., Arena, A., Gammeri, E., Bruno, M.E., Falagiani, P., Riva, G., et al. Parietaria sublingual allergoid immunotherapy with a co-seasonal treatment schedule. Allergol Immunopathol (Madr) 36 (2008), 79–84.
27. 27 Dichmann, R., Safety profile and compliance of co-seasonal initiation of specific sublingual immunotherapy with a perlingual spray application. Allergy 66 (2011), 631–632.
28. 28 Novembre, E., Galli, E., Landi, F., Caffarelli, C., Pifferi, M., De Marco, E., et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 114 (2004), 851–857.
29. 29 Ott, H., Sieber, J., Brehler, R., Folster-Holst, R., Kapp, A., Klimek, L., et al. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study. Allergy 64 (2009), 1394–1401.
30. 30 Reich, K., Gessner, C., Kroker, A., Schwab, J.A., Pohl, W., Villesen, H., et al. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis. Clin Ther 33 (2011), 828–840.
31. 31 Vervloet, D., Birnbaum, J., Laurent, P., Hugues, B., Fardeau, M.F., Massabie-Bouchat, Y.P., et al. Safety and efficacy of Juniperus ashei sublingual-swallow ultra-rush pollen immunotherapy in cypress rhinoconjunctivitis. Int Arch Allergy Immunol 142 (2007), 239–246.
32. 32 Nelson, H.S., Oral/sublingual Phleum pretense grass tablet (Grazax/Grastek) to treat allergic rhinitis in the USA. Expert Rev Clin Immunol 10 (2014), 1437–1451.
33. 33 Nolte, H., Amar, N., Bernstein, D.I., Lanier, B.Q., Creticos, P., Berman, G., et al. Safety and tolerability of a short ragweed sublingual immunotherapy tablet. Ann Allergy Asthma Immunol 113 (2014), 93–100.e3.
34. 34 Cox, L., Larenas-Linnemann, D., Lockey, R.F., Passalacqua, G., Speaking the same language: the World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. J Allergy Clin Immunol 125 (2010), 569–574 574.e1-7.
35. 35 Canonica, G.W., Cox, L., Pawankar, R., Baena-Cagnani, C.E., Blaiss, M., Bonini, S., et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J, 7, 2014, 6.
36. 36 Canonica, G.W., Baena-Cagnani, C.E., Bousquet, J., Bousquet, P.J., Lockey, R.F., Malling, H.J., et al. Recommendations for standardization of clinical trials with allergen specific immunotherapy for respiratory allergy: a statement of a World Allergy Organization (WAO) Taskforce. Allergy 62 (2007), 317–324.
37. 37 Senna, G., Caminati, M., Canonica, G.W., Safety and tolerability of sublingual immunotherapy in clinical trials and real life. Curr Opin Allergy Clin Immunol 13 (2013), 656–662.
38. 38 Horak, F., Zieglmayer, P., Zieglmayer, R., Lemell, P., Devillier, P., Montagut, A., et al. Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. J Allergy Clin Immunol 124 (2009), 471–477 477.e1.
39. 39 Nolte, H., Maloney, J., Nelson, H.S., Bernstein, D.I., Lu, S., Li, Z., et al. Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber. J Allergy Clin Immunol 135 (2015), 1494–1501 1501.e6.
40. 40 Demoly, P., Emminger, W., Rehm, D., Backer, V., Tommerup, L., Kleine-Tebbe, J., Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: results from a randomized double-blind, placebo-controlled phase III trial. J Allergy Clin Immunol 137 (2016), 444–451.
41. 41 Nayak, A.S., Atiee, G.J., Dige, E., Maloney, J., Nolte, H., Safety of ragweed sublingual allergy immunotherapy tablets in adults with allergic rhinoconjunctivitis. Allergy Asthma Proc 33 (2012), 404–410.
42. 42 Corzo, J.L., Carrillo, T., Pedemonte, C., Plaza Martin, A.M., Martin Hurtado, S., Dige, E., et al. Tolerability during double-blind randomized phase I trials with the house dust mite allergy immunotherapy tablet in adults and children. J Investig Allergol Clin Immunol 24 (2014), 154–161.
43. 43 Pfaar, O., Mosges, R., Hormann, K., Klimek, L., Safety aspects of cluster immunotherapy with semi-depot allergen extracts in seasonal allergic rhinoconjunctivitis. Eur Arch Otorhinolaryngol 267 (2010), 245–250.
44. Higgins J, Green S, (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
45. Chambers, D., Rodgers, M., Woolacott, N., Not only randomized controlled trials, but also case series should be considered in systematic reviews of rapidly developing technologies. J Clin Epidemiol 62 (2009), 1253–1260.e4.
46. Pfaar, O., Wolf, H., Klimek, L., Schnitker, J., Wustenberg, E., Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial. Clin Ther 34 (2012), 2072–2081.
47. Reich, K., Gessner, C., Kroker, A., Schwab, J.A., Pohl, W., Villesen, H., et al. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis. Clin Ther 33 (2011), 828–840.
48. Leonardi, S., Arena, A., Bruno, M.E., Cannao, P.M., D'Anneo, R.W., Falagiani, P., et al. Olea sublingual allergoid immunotherapy administered with two different treatment regimens. Allergy Asthma Proc 31 (2010), e25–e29.
49. Novembre, E., Galli, E., Landi, F., Caffarelli, C., Pifferi, M., De Marco, E., et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 114 (2004), 851–857.
50. D'Anneo, R.W., Arena, A., Gammeri, E., Bruno, M.E., Falagiani, P., Riva, G., et al. Parietaria sublingual allergoid immunotherapy with a co-seasonal treatment schedule. Allergol Immunopathol (Madr) 36 (2008), 79–84.
51. Pajno, G.B., Caminiti, L., Crisafulli, G., Vita, D., Valenzise, M., De Luca, R., et al. Direct comparison between continuous and coseasonal regimen for sublingual immunotherapy in children with grass allergy: a randomized controlled study. Pediatr Allergy Immunol 22 (2011), 803–807.
52. Reiber, R., Wolf, H., Schnitker, J., Wustenberg, E., Intra-seasonal short-time up-dosing with SQ-standardised subcutaneous immunotherapy in patients with intermittent allergic rhinoconjunctivitis is well tolerated during routine application: A non-interventional observational study. J Allergy Ther, 4, 2013, 137.
53. Lee, L.K., Kniker, W.T., Campos, T., Aggressive coseasonal immunotherapy in mountain cedar pollen allergy. Arch Otolaryngol 108 (1982), 787–794.
54. Klimek, L., Sager, A., Klein, C., Pfaar, O., INSIDE-safety and efficacy of an intraseasonal short-time subcutaneous immunotherapy with a modified depigmented birch-pollen extract. Allergy, 68, 2013, 478.
55. Vervloet, D., Birnbaum, J., Laurent, P., Hugues, B., Fardeau, M.F., Massabie-Bouchat, Y.P., et al. Safety and efficacy of Juniperus ashei sublingual-swallow ultra-rush pollen immunotherapy in cypress rhinoconjunctivitis. Int Arch Allergy Immunol 142 (2007), 239–246.
56. Bubel, P., Safety profile and compliance of co-seasonal initiation of specific subcutaneous immunotherapy with a highly polymerised allergen extract. Allergy, 65, 2010, 581.
57. Paterok, P., Co-seasonal initiation of cluster-immunotherapy with highly polymerised grass pollen extracts is a safe treatment. Allergy, 67, 2012, 234.
58. Werner, G., Cluster immunotherapy can be safely initiated extra and intra-seasonally for grass pollen allergic patients. Allergy, 68, 2013, 546.
59. Stelzer, T., Bubel, P., Tree pollen allergic patients can be safely treated with cluster immunotherapy. Allergy, 68, 2013, 586.
60. Schwab, J.A., Wolf, H., Schnitker, J., Wustenberg, E., Safety and tolerability of an intra-seasonal initiation of the sq-standardised grass allergy immunotherapy tablet: A non-interventional observational study investigating the feasibility during routine administration. Clinical Drug Investigation 33 (2013), 719–726.
61. Ariano, R., Incorvaia, C., La Grutta, S., Marcucci, F., Pajno, G., Sensi, L., et al. Safety of sublingual immunotherapy started during the pollen season. Curr Med Re Opin 25 (2009), 103–107.
62. Sieber, J., Koberlein, J., Mosges, R., Sublingual immunotherapy in daily medical practice: effectiveness of different treatment schedules - IPD meta-analysis. Curr Med Res Opin 26 (2010), 925–932.
63. Dichmann, R., Safety profile and compliance of co-seasonal initiation of specific sublingual immunotherapy with a perlingual spray application. Allergy 66 (2011), 631–632.
64. Ott, H., Sieber, J., Brehler, R., Folster-Holst, R., Kapp, A., Klimek, L., et al. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study. Allergy 64 (2009), 1394–1401.
65. Sieber, J., Neis, M., Brehler, R., Folster-Holst, R., Kapp, A., Klimek, L., et al. Increasing long-term safety of seasonal grass pollen sublingual immunotherapy: the ECRIT study. Expert Opin Drug Saf 11 (2012), 7–13.